Regulatory Readiness AGI operates with on-site breeding, CDC quarantine, and GLP study capabilities, signaling strong capability for regulated preclinical programs and potential upsell to sponsors seeking integrated colony management and compliant research workflows.

Vaccine and Gene Therapy Fit As the largest primate research organization supporting vaccine and gene therapy programs, AGI is well positioned to upsell expanded GLP studies, IND-enabling work, and long-term holding solutions for sponsors accelerating advanced therapeutics.

Scale and Longevity AGI’s on-site breeding and full-spectrum primate services cater to programs requiring continuous animal supply and rapid study turnover, presenting opportunities for multi-year contracts, increased capacity commitments, and bundled services.

Compliance and Risk Recent welfare concerns highlighted in December 2024 could prompt prospects to emphasize enhanced monitoring, third-party audits, and transparent reporting packages as part of a risk-mitigated outsourcing partnership.

Growth and Funding With revenue in the tens of millions and substantial funding backing, there is opportunity to engage clients seeking proven CRO partners with NIH/NIAID-related experience, leveraging past awards and contracts to demonstrate credibility for new programs.